Abstract 1605P
Background
Opevesostat is an oral, selective inhibitor of CYP11A1 that suppresses production of all steroid hormones and precursors. Initial phase 2 results in mCRPC patients with AR-LBD mutations were previously presented (ESMO 2022). Here we report phase 2 results for both AR-LBD mutation-positive and negative patients.
Methods
Opevesostat 5mg BID (with dexamethasone and fludrocortisone) was evaluated in open-label expansion in patients with progressive mCRPC following ≥1 line of 2nd generation AR-pathway inhibitor and ≥1 line of taxane-based chemotherapy. An initial cohort enrolled 45 patients with AR-LBD mutations in cell-free DNA (Guardant360), a subsequent extension included 89 mCRPC patients (21 and 68 pts with/without AR-LBD mutations respectively). Study objectives were safety and preliminary efficacy assessed by PSA and RECIST response and standard safety measures. Opevesostat was continued until disease progression or toxicity.
Results
Overall, 66 AR-LBD mutation-positive and 68 AR-LBD mutation-negative patients (median age 68.5 years) were enrolled. 53.0% and 36.8% had previously received both abiraterone and enzalutamide, and 69.7% and 64.7% had received cabazitaxel in patients with and without AR-LBD mutation respectively. Opevesostat treatment led to PSA50 responses in 53.0% and 14.7% of patients, and PSA30 responses in 68.2% and 29.4% of patients, with and without AR-LBD mutations respectively. At data cut-off (23 Jan 2024), objective responses by RECIST had occurred in 10 patients, 8 with AR-LBD mutations (ORR 18.6% for AR-LBD positive). Opevesostat was well-tolerated: hospitalisation for adrenal insufficiency-like syndrome was much lower than in phase 1 when typically higher opevesostat doses were administered (6.7% vs. 31.9% respectively). Duration of response and safety with a minimum follow up of approximately 6.5 months will be presented.
Conclusions
Administration of Opevesostat to heavily pre-treated mCRPC patients shows promising antitumor activity. PSA50 responses were most frequent among patients harbouring activating AR-LBD mutations.
Clinical trial identification
NCT03436485, First posted: 19 February 2018.
Editorial acknowledgement
Legal entity responsible for the study
Orion Corporation and Merck Sharp and Dohme.
Funding
Orion Corporation and Merck Sharp and Dohme.
Disclosure
K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer, Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Personal, Advisory Board, February 2022: Arvinas; Financial Interests, Personal, Advisory Board, April 2022: Macrogenics; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the CAPITELLO 281 phase 3 trial: AstraZeneca; Non-Financial Interests, Principal Investigator, Chair of the TALAPRO-2 and TALAPRO-3 phase 3 trials: Pfizer; Non-Financial Interests, Principal Investigator, Chair of the RADIANT phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the TRITON-3 phase 3 trial: Clovis. G. Roubaud: Financial Interests, Personal, Advisory Board: Janssen, Astellas, Bayer; Financial Interests, Institutional, Advisory Board: Pfizer, AstraZeneca; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Coordinating PI: Bayer. A. Bernard-Tessier: Financial Interests, Personal, Invited Speaker: Astellas, Bayer, AstraZeneca; Financial Interests, Personal, Other, travel fees: ORION; Financial Interests, Institutional, Advisory Board: Novartis, Roche, Janssen, MSD, AAA-Novartis; Financial Interests, Personal, Writing Engagement: Bouchara-Recordati; Non-Financial Interests, Principal Investigator: Amgen, Macrogenics, Janssen. G. Gravis: Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Ipsen, AstraZeneca, alliance Merck Pfizer, Bayer, Eisai; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer, BMS, Janssen, Pfizer, Ipsen, Bayer, EISAI; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS; Non-Financial Interests, Principal Investigator: IPSEN, BMS, Merck. A. Flechon: Financial Interests, Personal, Advisory Board: AstraZeneca, Astellas, Janssen, AAA, Bayer, MSD, Pfizer, Merck, BMS; Financial Interests, Personal, Invited Speaker: Novartis. R. Ratta: Financial Interests, Personal, Invited Speaker: Ipsen, Astellas; Financial Interests, Personal, Advisory Board: Pfizer, Merck, Bristol Meyer Squibb, AstraZeneca, Janssen. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca. R.J. Jones: Financial Interests, Personal, Advisory Board, advisory board attendance: AstraZeneca, Astellas; Financial Interests, Personal, Invited Speaker, Honoraria for speaking: Astellas; Financial Interests, Personal, Advisory Board: Bayer, Clovis, Exelixis, Ipsen, Bristol Myers Squibb, Merck Serono, Merck Sharpe Dome, Roche, Janssen, Novartis / AAA, MSD, ASTELLAS, Gilead, AstraZeneca, Pfizer; Financial Interests, Personal, Invited Speaker: Bayer, Ipsen, Bristol Myers Squibb, Merck Serono, Merck Sharpe Dome, Pfizer, Roche, Janssen, Pfizer; Financial Interests, Institutional, Other, IDMC membership: Roche; Financial Interests, Institutional, Other, IDMC member: Stab; Financial Interests, Personal, Other, promotional video: Astellas, Astellas, Astellas, Bayer; Financial Interests, Institutional, Local PI: Janssen, Pfizer, Tail, AstraZeneca, BioXcel, Bristol Myers Squibb; Financial Interests, Institutional, Coordinating PI: Novartis / AAA, Roche, MSK. A. Hussain: Financial Interests, Institutional, Local PI: AstraZeneca, Regeneron, Poseida, FutureChem, Pfizer, Bayer, Bristol Myers Squibb, Exelexis, PSI, Arravive, Nimbus, Infinity, Orion; Financial Interests, Institutional, Funding: Merck. N. Cook: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Institutional, Local PI: Taiho, Roche, AstraZeneca, Avacta, Bayer, Eisai, UCB, Boeringher, Stemline; Financial Interests, Institutional, Coordinating PI: RedX, Orion, Starpharma, LOXO-Oncology; Non-Financial Interests, Advisory Role: Roche; Non-Financial Interests, Other, Committee chair: Cancer Research UK. M.M.E. Tanner: Financial Interests, Personal, Advisory Role: Daiichi Sankyo, Novartis, Roche, Eli Lilly, AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Seagen; Financial Interests, Institutional, Research Funding: Novartis, Roche, Eli Lilly, Seagen, Orion Corporation. R.H. Jones: Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Institutional, Leadership Role: Roche. C. Garratt: Financial Interests, Personal, Full or part-time Employment: Orion Corporation; Financial Interests, Personal, Stocks/Shares: Orion Corporation. T. Ikonen: Financial Interests, Personal, Full or part-time Employment: Orion. P. Pohjanjousi: Financial Interests, Personal, Full or part-time Employment: Orion; Financial Interests, Personal, Stocks/Shares: Orion. C.H. Poehlein: Financial Interests, Personal, Full or part-time Employment, Employee and recipient of Stock: Merck & Co; Financial Interests, Personal, Stocks/Shares: Merck & Co; Non-Financial Interests, Member: ASCO, SITC, EAU. E.S. Antonarakis: Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Clovis, MacroGenics, Merck, Novartis, Seagen; Financial Interests, Institutional, Principal Investigator: Orion; Financial Interests, Personal, Advisory Role: Aadi Bioscience, Blue Earth Diagnostics, Curium, EcoR1, Hookipa Pharma, Lilly, Menarini Silicon Biosystems, Sanofi, Tango Therapeutics, Tempus, z-Alpha; Financial Interests, Institutional, Advisory Role: Amgen, AstraZeneca, Bayer, Janssen, Merck, Pfizer; Financial Interests, Institutional, Advisory Board: Orion. All other authors have declared no conflicts of interest.
Resources from the same session
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10